Background-Triiodothyronine (T 3 ) supplementation may be a useful adjunct in the management of patients after cardiopulmonary bypass. Limited data are available regarding the use and pharmacokinetics of T 3 in children. The present study was performed to evaluate T 3 pharmacokinetics in a cohort of children undergoing the modified Fontan procedure. Methods and Results-A total of 28 patients were enrolled in this randomized, prospective study. The patients were divided into 4 groups: 1 group received a placebo and 3 groups received intravenous T 3 at dosages of 0.4, 0.6, and 0.8 g/kg, respectively. All 28 patients survived their operative procedures. Two patients developed low cardiac output, and 3 patients had pleural effusions. The median length of hospital stay was 7 days. The mean free T 3 level was 316Ϯ67 pg/dL after then administration of a placebo. Patients who received T 3 had mean peak free T 3 levels of 972Ϯ88, 1351Ϯ299, and 1869Ϯ281 pg/dL for the dosages of 0.4, 0.6, and 0.8 g/kg, respectively. The calculated half-life of T 3 was 7 hours. Conclusions-The half-life of intravenous T 3 in children is approximately one-third of that reported for adults. These results provide a framework for studying the efficacy of T 3 supplementation in children undergoing open-heart surgery.
C ardiopulmonary bypass is associated with altered endocrine responses, including a marked reduction in thyroid hormone levels. 1, 2 Adult patients undergoing cardiopulmonary bypass demonstrate a 30% to 40% decrease in serum levels of free triiodothyronine (T 3 ), the form of thyroid hormone that has the greatest biological activity at the cellular level. Thyroid hormone has important effects on cardiovascular performance; these include increasing heart rate and contractility, improving diastolic function, and decreasing systemic vascular resistance. 3, 4 Changes in serum free T 3 levels correlate with changes in cardiac output through these mechanisms. The magnitude of reduced T 3 availability demonstrated in adult patients undergoing cardiopulmonary bypass may be sufficient to adversely affect cardiovascular performance postoperatively.
The recognition that cardiopulmonary bypass in adult patients results in significant reductions in free T 3 availability has led to an interest in providing supplemental T 3 to cardiotomy patients postoperatively as a means to improve myocardial performance. 5 Adult patients undergoing open-heart surgery who receive T 3 supplementation demonstrate a dose-dependent increase in cardiac output. 6 This increase in cardiac output not only lessens the need for other inotropic or mechanical circulatory support, 7 but is associated with improved outcome. 8 These clinical results have prompted animal investigations that have confirmed that T 3 has a benefit on both contractility 9 and ventriculoarterial coupling. 10 These results support the use of T 3 supplementation as a valuable adjunct in the management of adult patients undergoing cardiopulmonary bypass.
Children who are born with congenital heart disease may also have a need for open-heart surgery. Some of these procedures are complex and may be associated with a significant risk due to poor cardiac performance after the procedure. Preliminary studies indicate that children undergoing cardiopulmonary bypass experience reductions in serum free T 3 levels that are more profound than their adult counterparts. 11, 12 These observations suggest that T 3 supplementation could potentially be beneficial in pediatric patients undergoing open-heart surgery.
The clinical experience in adult patients and the research data in adult animals supporting the efficacy of T 3 supplementation may not be applicable to children undergoing cardiopulmonary bypass because of differences in the surgical procedures, postoperative hemodynamics, and the intrinsic metabolic rate. We previously evaluated the changes in thyroid hormone levels in children undergoing the modified Fontan procedure, which is an open-heart operation used for the treatment of patients born with a functional single ventricle. 13 This study indicated that patients undergoing the Fontan procedure demonstrated a 75% decrease in serum T 3 levels postoperatively. We also had preliminary experience with T 3 supplementation in this population that indicated the safety of T 3 supplementation at a relatively low dose. 14 However, before a study can be performed to assess the efficacy of T 3 treatment in children undergoing cardiopulmonary bypass, it is important to assess the pharmacokinetics of T 3 to determine an appropriate dosing regimen. The purpose of the present study was to evaluate the pharmacokinetics of T 3 supplementation in children undergoing the modified Fontan procedure.
Results
All 28 children survived the Fontan procedure (no operative mortality). For the entire group of patients, the median length of mechanical ventilation was 8 hours, the median length of time in the pediatric intensive care unit (PICU) was 72 hours, and the median length of hospital stay was 7 days. Patients 5 and 15 developed a low cardiac output that resolved with supportive care. Patient 5 had junctional tachycardia that contributed to her low cardiac output state. The 2 patients who had low cardiac outputs had the longest durations of mechanical ventilation and PICU stay, and both had hospital lengths of stay Ͼ10 days.
Patients 21, 22, and 23 developed pleural effusions, and these 3 patients accounted for the 3 longest lengths of hospital stay. No patient who received T 3 supplementation exhibited signs of hyperthyroidism, such as ventricular irritability, persistently elevated temperature, or unusual vasodilatation. Data for individual patients are shown in Table 1 .
The randomization process resulted in 7 patients who received the placebo. In the groups that received T 3 , 7 patients received a dose of 0.4 g/kg, 8 patients received a dose of 0.6 g/kg, and 6 patients received a dose of 0.8 g/kg. The 4 groups were similar in age, weight, age at bidirectional Glenn procedure, interval between bidirectional Glenn and Fontan procedures, cross-clamp time, and cardiopulmonary bypass time (Table 2) . Both patients who developed low cardiac output were in the group that received a dose of 0.6 g/kg T 3 . Of the 3 patients who developed pleural effusions, 1 received 0.6 g/kg T 3 , and 2 received 0.8 g/kg T 3 . Statistical analysis revealed that the length of PICU stay was longer in the group that received 0.6 g/kg because 3 patients in this group had complications of low cardiac output or pleural effusion. Serum free T 3 levels for the 4 groups are shown in Figure 1 . Baseline values were similar in all groups. Peak free T 3 serum levels measured 10 minutes after the administration of T 3 were 972Ϯ88, 1351Ϯ313, and 1869Ϯ281 pg/dL, respectively, for groups 2 through 4, and 313Ϯ60 pg/dL in the placebo group (group 1). Serum free T 3 levels were again similar in all groups 12 and 24 hours after T 3 administration. The calculated half-lives of T 3 were 7.0Ϯ1.0, 7.3Ϯ1.1, and 7.0Ϯ0.9 hours, respectively, in groups 2 through 4. The areas under the curve attributable to T 3 administration for serum free T 3 were 2160Ϯ729, 3446Ϯ1120, and 5085Ϯ1673 pg ⅐ hr/dL, respectively, for groups 2 through 4. Serum total T 3 levels for the 4 groups are shown in Figure 2 . Baseline total T 3 levels were similar in the 4 groups, but they 
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increased to peak levels of 314Ϯ28, 383Ϯ81, and 494Ϯ105 ng/dL, respectively, for the 3 doses of T 3 , compared with 105Ϯ23 ng/dL for the placebo group. Total T 3 levels were similar in all groups at 6, 12, 24, 48, and 72 hours postoperatively. The areas under the curves attributable to T 3 administration for serum total T 3 were 707Ϯ203, 1207Ϯ428, and 1564Ϯ591 ng ⅐ hr/dL, respectively, for groups 2 through 4. The volume of distribution of the central compartment was 0.17Ϯ0.05 L/kg, and the volume of distribution at a steady state was 0.31Ϯ0.09 L/kg. Data for reverse T 3 levels are summarized in Figure 3 . Reverse T 3 levels were similar in all groups at baseline, but they increased significantly at 24 hours postoperatively. Reverse T 3 levels then began to return to baseline values, with the greatest fall in reverse T 3 levels seen in the groups that received 0.6 and 0.8 g/kg T 3 supplementation.
The thyroid stimulating hormone (TSH) and thyroglobulin data are summarized in Table 3 . Although baseline TSH levels were somewhat disparate among the 4 groups, a significant increase in TSH levels existed in each group at 5 days when compared with the baseline levels for that group. Similarly, thyroglobulin levels increased significantly at 5 days when compared with the baseline values for each group.
Free and total T 3 data are shown in Figure 4 for the 5 patients who developed postoperative complications (2 patients with low cardiac output and 3 with pleural effusions). Children who experienced low cardiac output had persistently low T 3 levels at 72 and 120 hours, whereas children with pleural effusions demonstrated some recovery of T 3 levels at 120 hours. Figure 5 demonstrates the free and total T 3 levels from 24 to 120 hours postoperatively for the 19 patients who did not experience complications and for the 5 who did experience a complication. At 120 hours, patients who received supplemental T 3 had higher serum T 3 levels than those who received placebo.
However, the placebo group had higher serum free and total T 3 levels than patients who developed low cardiac output or pleural effusions.
All the patients enrolled in this study are alive. The mean duration of follow-up is 24Ϯ5 months. Two patients in this cohort have undergone subsequent procedures: one had plication of a hemidiaphragm, and the other had closure of a "baffle leak." 
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The modified Fontan procedure is used to separate the systemic and pulmonary circulations in children born with a functional single ventricle. Although the results of this procedure have improved dramatically over the past 15 years, 15, 16 the Fontan operation is still associated with a significant mortality rate. Low cardiac output remains the most common cause of mortality. The causes of low cardiac output after the Fontan procedure are multifactorial, and they include increased pulmonary vascular resistance, mechanical obstruction, inadequate myocardial protection, and diastolic dysfunction. Previous studies have shown that patients undergoing the Fontan procedure have marked reductions in their serum free T 3 levels, 13 and this may contribute to the incidence of low cardiac output after this procedure. The present study was performed to evaluate the pharmacokinetics of T 3 supplementation after the modified Fontan procedure. The results of this study demonstrate a dose-dependent increase in peak serum free T 3 levels, with free T 3 levels returning to baseline within 12 hours. The calculated half-life of free T 3 was 7 hours. The study also confirmed the safety of T 3 supplementation in children in a dose ranging from 0.4 to 0.8 g/kg, because no complications occurred that were perceived to be attributable to T 3 supplementation.
The children who received placebo demonstrated decreases in free and total T 3 levels that reached a nadir at 48 hours postoperatively. These results are quantitatively and qualitatively similar to those previously reported. 13 The cause of this decline in T 3 levels is probably multifactorial but may include factors such as fasting, anesthetic agents, and surgical stress, as well as the administration of dopamine 17 and steroids. 18 The present study also demonstrated an increase in reverse T 3 levels at 24 hours postoperatively, a finding that is consistent with the euthyroid sick syndrome. 19 The exact cause of euthyroid sick syndrome is unknown; however, experimentally, it has been related to the generation of cytokines, tumor necrosis factor, 20 and interleukin-1␤. 21 T 3 supplementation at doses between 0.4 and 0.8 g/kg resulted in a dose-dependent increase in both free and total serum T 3 levels. This increase in serum T 3 levels in response to T 3 supplementation was short-lived, because the calculated half-life for free T 3 was 7 hours. The half-life of supplemental T 3 in adult patients undergoing cardiopulmonary bypass was previously reported as 24 hours, 22 or Ϸ3-fold longer than that observed in the present study. These results suggest that children undergoing cardiopulmonary bypass who receive T 3 supplementation may require higher or more frequent dosing to demonstrate its efficacy in this population.
Patients who received T 3 supplementation demonstrated significant differences in the late phase of their endocrinologic response when compared with patients who received placebo. Patients who received T 3 supplementation had higher serum free and total T 3 levels, higher TSH levels, and lower reverse T 3 levels at 120 hours when compared with the placebo group. These findings are similar to our previous observations 14 and indicate that T 3 supplementation results in enhanced recovery of the pituitary-thyroid axis. Although a more rapid recovery of the pituitary-thyroid axis may correlate with the improved recovery of the individual, this association has not been proven.
In summary, the administration of exogenous T 3 to children undergoing the modified Fontan procedure results in a dosedependent increase in serum peak free T 3 levels. The serum half-life of T 3 in this patient population was approximately one-third of that previously reported in adults. The administration of supplemental T 3 was associated with a more rapid endocrinologic recovery. T 3 supplementation was not associated with adverse reactions, suggesting that this is a safe drug in the dose range of 0.4 to 0.8 g/kg. Future studies evaluating the efficacy of T 3 supplementation in children undergoing open-heart surgery can now be undertaken using this study of pharmacokinetics.
